VRCA
Income statement / Annual
Last year (2024), Verrica Pharmaceuticals Inc.'s total revenue was $7.57 M,
an increase of 47.66% from the previous year.
In 2024, Verrica Pharmaceuticals Inc.'s net income was -$76.58 M.
See Verrica Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$7.57 M |
$5.12 M |
$9.03 M |
$12.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$2.74 M
|
$746.00 K
|
$725.00 K
|
$472.00 K
|
$229.00 K
|
$257.20 K
|
$20.29 K
|
$0.00
|
$0.00
|
| Gross Profit |
$4.83 M
|
$4.38 M
|
$8.31 M
|
$11.53 M
|
-$229.00 K
|
-$257.20 K
|
-$20.29 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.64
|
0.85
|
0.92
|
0.96
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.84 M
|
$20.30 M
|
$12.20 M
|
$15.93 M
|
$15.67 M
|
$15.44 M
|
$12.83 M
|
$3.73 M
|
$1.71 M
|
| General & Administrative Expenses |
$0.00
|
$47.30 M
|
$17.41 M
|
$26.98 M
|
$24.51 M
|
$0.00
|
$9.05 M
|
$727.00 K
|
$204.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$3.50 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$58.82 M
|
$47.31 M
|
$17.41 M
|
$26.98 M
|
$24.51 M
|
$14.39 M
|
$9.05 M
|
$727.00 K
|
$204.00 K
|
| Other Expenses |
$83.00 K
|
$2.54 M
|
$0.00
|
-$472.00 K
|
-$229.00 K
|
$0.00
|
-$1.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$70.75 M
|
$70.14 M
|
$29.60 M
|
$42.44 M
|
$39.95 M
|
$29.82 M
|
$21.88 M
|
$4.46 M
|
$1.91 M
|
| Cost And Expenses |
$73.49 M
|
$70.88 M
|
$30.33 M
|
$42.91 M
|
$40.18 M
|
$30.08 M
|
$21.88 M
|
$4.46 M
|
$1.91 M
|
| Interest Income |
$1.42 M
|
$2.74 M
|
$476.00 K
|
$123.00 K
|
$521.00 K
|
$1.88 M
|
$1.23 M
|
$0.00
|
$0.00
|
| Interest Expense |
$9.41 M
|
$3.96 M
|
$2.17 M
|
$4.30 M
|
$3.03 M
|
$0.00
|
$0.00
|
$2.00 K
|
$0.00
|
| Depreciation & Amortization |
$1.27 M
|
$836.00 K
|
$718.00 K
|
$472.00 K
|
$229.00 K
|
$257.20 K
|
$20.29 K
|
$4.46 M
|
$1.91 M
|
| EBITDA |
-$65.90 M |
-$62.20 M |
-$21.60 M |
-$30.31 M |
-$39.43 M |
-$27.95 M |
-$20.63 M |
-$4.46 M |
-$1.91 M |
| EBITDA Ratio |
-8.71
|
-12.14
|
-2.39
|
-2.53
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-8.71
|
-12.83
|
-2.36
|
-2.58
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$10.66 M
|
-$1.24 M
|
-$3.19 M
|
-$4.17 M
|
-$2.51 M
|
$1.87 M
|
$1.23 M
|
-$2.00 K
|
$0.00
|
| Income Before Tax |
-$76.58 M
|
-$67.00 M
|
-$24.49 M
|
-$35.08 M
|
-$42.69 M
|
-$28.21 M
|
-$20.65 M
|
-$4.46 M
|
-$1.91 M
|
| Income Before Tax Ratio |
-10.12
|
-13.07
|
-2.71
|
-2.92
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$76.58 M
|
-$67.00 M
|
-$24.49 M
|
-$35.08 M
|
-$45.50 M
|
-$28.21 M
|
-$20.65 M
|
-$4.46 M
|
-$1.91 M
|
| Net Income Ratio |
-10.12
|
-13.07
|
-2.71
|
-2.92
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-14.78 |
-14.78 |
-7.17 |
-12.97 |
-17.08 |
-11.33 |
-14.0819 |
-3.7978 |
-0.7445 |
| EPS Diluted |
-14.78 |
-14.78 |
-7.17 |
-12.97 |
-17.08 |
-11.33 |
-14.0819 |
-3.7978 |
-0.7445 |
| Weighted Average Shares Out |
$5.18 M
|
$4.53 M
|
$3.42 M
|
$2.70 M
|
$2.50 M
|
$2.49 M
|
$1.47 M
|
$2.57 M
|
$2.57 M
|
| Weighted Average Shares Out Diluted |
$5.18 M
|
$4.53 M
|
$3.42 M
|
$2.70 M
|
$2.50 M
|
$2.49 M
|
$1.47 M
|
$2.57 M
|
$2.57 M
|
| Link |
|
|
|
|
|
|
|
|
|
